Background: Although there has been abundant research on chronic low-grade inflammation as a potential mechanism underlying the link between mood disorders and cardiovascular risk, less is known about the role of inflammatory factors and anxiety disorders. The aim of this paper is to evaluate the bi-directional associations between inflammatory markers including interleukin (IL)-6, tumor necrosis factor (TNF)-α, and high sensitivity C-reactive protein (hsCRP) with anxiety disorders and its subgroups.
Methods: The sample consisted of 3,113 participants (53.7% women; mean age: 51.0, S.D. 8.8 years), randomly selected from the general population, who underwent comprehensive somatic and psychiatric evaluations at baseline and follow-up (mean follow-up duration = 5.5 years, S.D. 0.6). Anxiety disorders were assessed with semistructured diagnostic interviews. Inflammatory biomarkers were analyzed in fasting blood samples.
Results: After adjustment for potential confounders, current anxiety disorders (β = 0.09, 95% CI 0.00-0.17) and agoraphobia (β = 0.25, 95% CI: 0.07-0.43) at baseline were associated with a steeper increase of hsCRP levels over the follow-up period. Current posttraumatic stress disorder (PTSD) was associated with a lower increase of IL-6 levels over the follow-up period (β = -0.52, 95% CI: -1.00/-0.04). There was no evidence for an association between inflammation markers at baseline and anxiety disorders at follow-up.
Conclusions: The prospective association between agoraphobia at baseline and hsCRP levels over the follow-up period suggests that chronic low-grade inflammation may be a consequence of this condition. The decrease in IL-6 in PTSD also requires further investigation. No evidence was found for chronic low-grade inflammation as a predictor of future anxiety disorders.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/da.22710 | DOI Listing |
Soc Neurosci
January 2025
Department of Food Science and Nutrition, Daegu Catholic University, Gyeongsan, Republic of Korea.
Social behavior is affected by social structure type, but how neural function changes with social type remains unclear. We investigated whether social group size affects social behaviors based on dopamine (DA) and serotonin (5-HT) systems. Four-week-old male mice were housed under different social group sizes: one, two, four, and eight mice per cage (1mpc, 2mpc, 4mpc, 8mpc, respectively).
View Article and Find Full Text PDFBrain Behav Immun
January 2025
Neuropsychiatry Centre, The Royal Melbourne Hospital, Melbourne, Australia; Department of Psychiatry, University of Melbourne, Melbourne, Australia. Electronic address:
Actas Dermosifiliogr
January 2025
Department of Dermatology, Hospital Universitario Miguel Servet IIS Aragón, Zaragoza, Spain.
Background: Psoriasis is a chronic disease with a prevalence of 3% in the general population. The high prevalence of psoriasis has prompted the study of its comorbidities in recent decades. However, no studies have ever analyzed comorbidity patterns including all chronic diseases in psoriatic patients.
View Article and Find Full Text PDFJ Affect Disord
January 2025
Department for Clinical Psychology and Psychotherapy, University of Freiburg, Germany. Electronic address:
Background: Increased emotional reactivity to stress, emotional dysregulation and sleep disturbances are interdependent trans-diagnostic processes that are present in internalising disorders such as depression and anxiety disorders. This study investigated which objective and subjective parameters of stress reactivity, sleep and emotional processing would predict symptoms of anxiety and depression in adolescents and young adults.
Methods: Participants were adolescents and young adults between the ages of 14 to 21 (N = 106, 25[24 %] male, M age = 17.
Pharmacol Ther
January 2025
Research Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Sciences, Tabriz, Iran; Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address:
While benzodiazepines have been a mainstay of the pharmacotherapy of anxiety disorders, their short-term efficacy and risk of abuse have driven the exploration of alternative treatment approaches. The endocannabinoid (eCB) system has emerged as a key modulator of anxiety-related processes, with evidence suggesting dynamic interactions between the eCB system and the GABAergic system, the primary target of benzodiazepines. According to the existing literature, the activation of the cannabinoid receptors has been shown to exert anxiolytic effects, while their blockade or genetic deletion results in heightened anxiety-like responses.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!